Drug Shortage Prevention Act of 2025
- Sponsor
- Sen. Klobuchar, Amy [D-MN]
- Committees
- Health, Education, Labor, and Pensions Committee (primary)
- Last action
- Aug 1, 2025
Bottom line
This bill aims to prevent drug shortages by enhancing manufacturer transparency and early warning systems for the FDA regarding critical drug supply chain vulnerabilities and demand surges.
What it actually does
The bill expands existing drug shortage notification requirements for manufacturers of critical drugs to include circumstances like increased demand or export restrictions, requiring earlier and more detailed reporting to the FDA. It also mandates semi-annual reporting on the supply chain for active pharmaceutical ingredients and intermediate materials, including supplier identities and quantities sourced.
Proponents argue
Supporters argue that the bill will provide the FDA with crucial early warning signals, allowing proactive intervention to prevent drug shortages that can endanger patient health. By requiring notification of increased demand and detailed supply chain mapping, the FDA can better understand and address vulnerabilities before they escalate into full-blown shortages, ultimately improving public health preparedness and patient access to essential medicines.
Opponents contend
Critics might contend that the expanded reporting requirements impose significant new administrative and compliance burdens on drug manufacturers, potentially increasing costs that could be passed on to consumers or disincentivizing production of certain critical drugs. Concerns could also be raised about the proprietary nature of detailed supply chain information and the potential for unintended consequences if this data is not handled securely or if it creates competitive disadvantages.
The bill is relatively short and its core provisions are clearly stated, making it accessible for an informed reader to understand its implications within a reasonable timeframe.
Section 2(a)(2), amending 21 U.S.C. 356c(a)(1)(A)(iii)
Mandating Notification for Increased Demand and Other Supply Disruptions
This provision requires manufacturers of critical drugs to notify the FDA not only of manufacturing discontinuances or interruptions, but also of any other circumstances, such as a surge in demand or export restrictions, that are likely to prevent them from meeting demand without a significant shortfall or delay. This aims to provide the FDA with earlier warnings about potential drug shortages.
Supporters argue
Supporters argue this is a critical step to move from reactive to proactive drug shortage management. By requiring notification of demand increases or export restrictions, the FDA can anticipate and address supply issues before they become crises, ensuring patients have access to life-saving medications.
Critics contend
Some manufacturers might argue that predicting future demand shortfalls or the impact of export restrictions is complex and could lead to over-reporting or reporting based on uncertain forecasts, creating unnecessary administrative burdens and potentially diverting resources from drug production.
Tradeoffs
The provision balances the need for early warning signals to prevent shortages against the potential for increased reporting burden on manufacturers and the challenge of accurately forecasting future demand or external supply chain impacts.
Section 2(a)(2), amending 21 U.S.C. 356c(b)(2)
Expedited Notification for Demand-Related Shortage Risks
This provision sets a new, expedited timeline for manufacturers to report circumstances like increased demand or export restrictions. While manufacturing discontinuances still require 6 months' notice, these new demand-side or external factors must be reported "as soon as practicable, or not later than 10 business days after the onset of the circumstance."
Section 3, amending 21 U.S.C. 360(j)(3)(A)
Semi-Annual Reporting on API and Intermediate Material Suppliers
This provision significantly expands the information drug manufacturers must report to the FDA regarding their supply chains. Instead of annual reporting, it requires semi-annual reports (March and September) detailing the legal names of suppliers for active pharmaceutical ingredients (APIs) and intermediate/in-process materials, along with the amount of drug manufactured using materials from each supplier.
The bill explicitly excludes "radiopharmaceutical drug product or any other product as designated by the Secretary" and "biological product (as defined in section 351(i) of the Public Health Service Act), unless otherwise provided by the Secretary in the regulations promulgated under subsection (i)" from the definition of a "covered drug." This means the new notification requirements do not apply to these categories by default.
Section 2(b), amending 21 U.S.C. 356c(h)(1)(B) and (C)
Why it matters:This is standard legislative practice to define scope and exclusions within a definitions section. It's not necessarily evasive, but it's a critical detail for understanding the bill's full reach.
Case for: Proponents might argue that these exclusions are necessary to avoid over-burdening specific sectors (like radiopharmaceuticals with unique supply chains) or to allow the Secretary flexibility to include biological products later if deemed appropriate, rather than a blanket inclusion that might not fit existing regulatory frameworks.
Case against: Critics could argue that excluding biological products, which include many vaccines and advanced therapies, from these critical shortage prevention measures creates a significant loophole, leaving a substantial portion of essential medicines vulnerable to unaddressed supply chain risks.
Estimated impact: Limits the scope of the bill's new notification requirements, potentially excluding a significant category of critical medicines (biological products) unless the Secretary explicitly includes them via regulation.